BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//The European School of Multimodality Imaging & Therapy (ESMIT) - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://esmit.eanm.org
X-WR-CALDESC:Events for The European School of Multimodality Imaging & Therapy (ESMIT)
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Europe/Vienna
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20230326T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20231029T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20240331T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20241027T010000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:+0100
TZOFFSETTO:+0200
TZNAME:CEST
DTSTART:20250330T010000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:+0200
TZOFFSETTO:+0100
TZNAME:CET
DTSTART:20251026T010000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=Europe/Vienna:20241202T100000
DTEND;TZID=Europe/Vienna:20241202T110000
DTSTAMP:20260422T034817
CREATED:20240702T080051Z
LAST-MODIFIED:20241119T122958Z
UID:1737-1733133600-1733137200@esmit.eanm.org
SUMMARY:Japanese vs. European View on Amyloid Imaging and Therapy (in collaboration with JSNM)
DESCRIPTION:The advent of FDA approved anti-AB drugs such as Aducanumab and Lecanemab is changing not only the therapeutic prospectives for patients but also the diagnostic flow-charts. However\, due to differences in clinical processes and insurance systems in each country\, the use of amyloid PET in the diagnostic tree currently varies from country to country. In Europe\, CSF diagnosis is often performed first and amyloid PET is performed in selected patients. In Japan\, only either CSF diagnosis or amyloid PET is covered by public insurance\, so there is a trend toward performing the more expensive PET first. The use of amyloid PET in the setting of anti-AB therapy monitoring\, and its exact positioning in the biomarkers  flow-chart is not yet clearly defined. This webinar will present recent findings on the usefulness of amyloid PET and the differences in actual use between Europe and Japan. \n\n\n\nLearning Objectives: tba \n\n\n\n\n\n\n\nSave yourself a FREE seatEnter the eLearning store to register for the course. Having trouble? See the short tutorial here. Register now FOR FREE!\n\n\n\n\n\n\n\nFaculty\n\n\n\n\n\nDonatienne Van WeehaegheModerator \n\n\n\n\n\n\n\n\n\n\n\nProf. Dr. med. Dr. biol. hum. Matthias Brendel\, MHBASpeakerDepartment leadBoard certified Nuclear Medicine physician Research lead for neurodegenerative disorders LMU Klinikum   Department of Nuclear MedicineUniversity Hospital of Munich \n\n\n\n\n\nDr. Kenji IshiiSpeakerDirectorDiagnostic Neuroimaging ResearchTokyo Metropolitan Institute for Geriatrics and GerontologyTokyo\, Japan \n\n\n\n\n\n\n\n\n\nRegistration\n\n\n\n\nmyEANM accountLog into your myEANM account or create a new one. \n\n\n\nESMIT eLearningAccess the eLearning platform. You can also navigate to it directly from your myEANM database: ESMIT→ESMIT Registrations \n\n\n\neLearning Course StoreEnter the course store\, make your selection and check out. \n\n\n\nEnroll yourselfFind your desired webinar under ‘Single Webinar Tickets’ or enroll for all 2024 webinars with the eLearning Access Plan – FREE OF CHARGE \n\n\n\nEnjoy!The link for the Zoom Webinar will be made available to you on the eLearning platform in the course contents \n\n\n\n\n\n\n\n\nEvent Overview
URL:https://esmit.eanm.org/event/japanese-vs-european-view-on-amyloid-imaging-and-therapy-in-collaboration-with-jsnm/
CATEGORIES:Clinical Nuclear Medicine,Live Webinars
END:VEVENT
END:VCALENDAR